Adrenoleukodystrophy (ALD) is a rare genetic disorder that affects approximately 1 in 18,000 people. It is characterized by a defect in the metabolism of very long chain fatty acids (VLCFAs) in the body and brain.
VLCFAs, which have at least 22 carbons, cannot be metabolized in the mitochondria, a specialized sac within eukaryotic cells. Instead, the peroxisome sacs in eukaryotic cells are responsible for metabolizing these fatty acids.
However, individuals with ALD have a malfunction in this process, leading to an accumulation of VLCFAs in the body. These excess fatty acids invade the brain and adrenal cortex, causing damage to the myelin sheath, which is responsible for insulating the nerve cells in the brain.
The consequences of ALD can be severe and painful. The damage to the myelin sheath can result in a variety of neurological symptoms, including cognitive decline, difficulty with coordination and movement, and changes in behavior. The severity and progression of the disease can vary widely among affected individuals.
Early detection and treatment are crucial in managing ALD. Treatment options may include medication to lower VLCFA levels, dietary modifications, and stem cell transplantation in certain cases.
Research and awareness of ALD continue to advance, providing hope for improved understanding, diagnostic methods, and treatment options for individuals affected by this rare disorder.
Genetic Link
Adrenoleukodystrophy is caused by an abnormality in the ABCD1 gene found on the X chromosome. This gene is responsible for producing the adrenoleukodystrophy protein in the peroxisomes. The condition is considered an X-linked recessive genetic disorder, meaning that women are generally better protected due to their extra X chromosome, while men tend to experience more severe effects.
The symptoms of adrenoleukodystrophy can vary depending on the subtype. However, since the condition affects the white matter of the central nervous system and adrenal cortex, neurological abnormalities are commonly observed.
Childhood-Onset Cerebral ALD
Childhood-onset cerebral ALD, also known as X-linked adrenoleukodystrophy (X-CALD), accounts for 45 percent of all ALD cases. This subtype of the disease typically manifests between the ages of four and ten. Initially, affected boys may exhibit cognitive dysfunction and withdrawal. Over time, symptoms progress to include deafness, blindness, and eventually dementia. Unfortunately, the prognosis for X-CALD is often grim, with most patients succumbing to the disease within two to five years of symptom onset. Detection of X-CALD can be aided by antenatal genetic testing and measuring VLCFA concentrations in plasma.